Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies-Reference-Cited by-同舟云学术

Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies

Published:2023-04-20 Issue:3 Volume:4 Page:172-175
ISSN:2643-3230
Container-title:Blood Cancer Discovery
language:en
Short-container-title:

Author:

Zitvogel Laurence¹²³⁴^ORCID,Derosa Lisa¹²³⁴^ORCID,Kroemer Guido⁵⁶⁷^ORCID

Affiliation:

1. 1Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.

2. 2Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

3. 3Institut National de la Santé Et de la Recherche Medicale (INSERM) U1015, Équipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.

4. 4CICBT1428 BIOTHERIS, GRCC, Villejuif Cedex, France.

5. 5Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.

6. 6Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.

7. 7Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France.

Abstract

Summary: In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD–specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).

Publisher

American Association for Cancer Research (AACR)

Subject

General Medicine

Link

https://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BCD-22-0213/3324783/bcd-22-0213.pdf

Reference10 articles.

1. SARS-CoV-2 Omicron variant: recent progress and future perspectives;Fan;Signal Transduct Target Ther,2022

2. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum;Tuekprakhon;Cell,2022

3. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure;Reynolds;Science,2022

4. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine;Launay;N Engl J Med,2022

5. The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in patients with cancer and healthy individuals;Fahrner;Cancer Discov,2022